Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 6 of 6 publications.
Skip to main content
Smith MR, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Le Berre MA, Mohamed AF, Odom D, Bartsch J, Snapir A, Sarapohja T, Fizazi K. Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial. Eur J Cancer. 2021 Jul 14;154:138-46.
Cella D, Hackshaw MD, Vondeling GT, Bennett L, Garbinsky D, Saito K, Sugihara M, Bang YJ, Yamaguchi K, Shitara K. Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial. Poster presented at the 2021 ASCO Conference; June 4, 2021. [abstract] J Clin Oncol. 2021; 39(Suppl 15):4057. doi: 10.1200/JCO.2021.39.15_suppl.4057
Sherrill B, Sherif B, Amonkar MM, Maltzman J, O'Rourke L, Johnston S. Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. Curr Med Res Opin. 2011 Dec 1;27(12):2245-52.
Sinha R, Byrtek M, DeJoubner NJ, Nooka AK, Taylor M, Cerhan JR, Ziemiecki RM. Examining the outcomes of watchful waiting (WW) among US patients with advanced stage follicular lymphoma (FL). Presented at the 53rd American Society of Hematology (ASH) Annual Meeting and Exposition; December 2011. San Diego, CA. [abstract] Blood. 2011 Nov 18; 118(21):775. doi: 10.1182/blood.V118.21.775.775
Sherrill B, Sherif BN, Amonkar M, Wu Y, Maltzman J, O'Rourke L, Johnston S. Quality of life and quality-adjusted survival (Q-TWIST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, her2+ metastatic breast cancer. Poster presented at the Cancer Symposium of the American Society of Clinical Oncology; October 10, 2009.
Sherrill EH, Sherif BN, Amonkar MM, Wu Y, Maltzman J, O'Rourke L, Johnston S. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, HER2+ metastatic breast cancer (MBC). Poster presented at the ASCO Breast Cancer Symposium; 2009.